Latest Articles

Publication Date
Role of hormonal therapies in endometriosis: balancing efficacy and safety.

Endometriosis is a chronic, estrogen-dependent inflammatory disorder requiring long-term management strategies that balance efficacy with systemic safety. Although hormonal therapies remain the cornerstone of treatment, the optimal degree of estrogen …

Published: June 10, 2026, midnight
Multiple recurrences of postmenopausal endometriosis associated with estrogen pellet therapy: clinical implications for hormone therapy and surgical management.

To challenge the perception that endometriosis uniformly regresses after menopause by presenting the case of repeated, pathology-confirmed symptomatic recurrences spanning two decades after menopause, and to emphasize key considerations for …

Published: June 9, 2026, midnight
The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years - MSN

The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years MSN

Published: June 8, 2026, 8:37 p.m.
Breaking the endometriosis-stroke axis: lesion-focused hydrogel reprogramming of thromboinflammatory networks.

Endometriosis is a chronic, systemic inflammatory disorder characterized by the ectopic implantation of endometrial-like tissue and accompanied by persistent pain and infertility. Beyond the pelvis, accumulating epidemiological evidence indicates that …

Published: June 8, 2026, midnight
Anti-NRP1 peptide-engineered ROS/pH dual-responsive nanoparticles for Alpelisib delivery regulate Sema3A-NRP1/PI3K-AKT signaling to balance oxidative stress and inhibit angiogenesis in endometriosis.

Endometriosis progression is driven by oxidative stress and excessive angiogenesis within an inflammatory microenvironment. To overcome these challenges, we designed ROS/pH dual-responsive Alpelisib-loaded nanoparticles (Alp@TAT-AT7-NPs) functionalized with an anti-NRP1 peptide …

Published: June 6, 2026, midnight
Women ‘blindsided’ as critical hormone therapy pulled from shelves - Herald Sun

Women ‘blindsided’ as critical hormone therapy pulled from shelves Herald Sun

Published: June 4, 2026, 8:38 p.m.
FOCL: Robotic focal therapy growth accelerates with HIFU innovation, new indications, and global expansion - TradingView

FOCL: Robotic focal therapy growth accelerates with HIFU innovation, new indications, and global expansion TradingView

Published: June 4, 2026, 7:18 p.m.
Women ‘blindsided’ as critical hormone therapy pulled from shelves - NT News

Women ‘blindsided’ as critical hormone therapy pulled from shelves NT News

Published: June 4, 2026, 4:21 a.m.
Women ‘blindsided’ as critical hormone therapy pulled from shelves - The Cairns Post

Women ‘blindsided’ as critical hormone therapy pulled from shelves The Cairns Post

Published: June 4, 2026, 4:20 a.m.
Psychological flexibility and pain catastrophizing in endometriosis: Incremental validity and interaction effects in predicting psychosocial outcomes.

Psychological distress and reduced health-related quality of life are common among women with endometriosis, particularly when the condition is accompanied by chronic pain. Psychological flexibility (PF), a core process in …

Published: June 4, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!